CSL is seeing improved plasma collection as places like the US start to return to normal. Additionally the Vifor acquisition should complete in the next few months with the potential for the stock to re-rate higher. The stock has formed an ascending triangle formation with resistance being tested on multiple occasions at the 273/274 level at which a major stock placement to fund the Vifor acquisition was recently conducted. A breakout at 274 was observed with the stock pulling back to retest that level as support. With improving fundamentals and a bullish chart formation, I think this stock is good for a trade. Targetting 297 to the upside as measured by triangle width and aligning with level from which the stock fell when the recent placement was announced. Placing stops just below the ascending trendline.